Start here if you're new
what it is
AbCellera finds antibody drugs for partners and is now trying to turn that platform into its own medicine pipeline.
how it gets paid
FY2024 revenue was $28.8M, down from $38.0M in 2023 (AbCellera FY2024 business results).
why it's growing
Revenue fell year over year as milestone timing shifted; net loss was $162.9M ($(0.55) per share) for FY2024.
what just happened
Use the latest 10‑Q for quarter‑to‑quarter revenue; the FY2024 full‑year figure is the anchor above.
At a glance
B balance sheet — gets the job done, barely
negative earnings — ROC not meaningful until profitable
-$0.55 fy2024 eps est
$28.8M FY2024 revenue (reported)
n/a operating margin
xvary composite: 47/100 — below average
What they do
AbCellera finds antibody drugs for partners and is now trying to turn that platform into its own medicine pipeline.
You are not buying one lab asset. You are buying a 596-employee antibody discovery machine tied to big partners like Eli Lilly, Biogen, Viking Global, and ArrowMark. The edge is speed and repetition: more shots on goal across cancer, autoimmune, and metabolic disease, while smaller biotechs usually bet the company on one or two programs.
How they make money
$28.8M
FY2024 revenue · down vs. 2023 on partnership/milestone timing
total revenue
$28.8M
YoY
The products that matter
discovers partner antibody candidates
Antibody Discovery Platform
100+ partner programs
this is the core business. more than 100 partner programs create milestone and royalty optionality, but FY2024 revenue was only $28.8M—scale has not turned into steady cash flow yet.
platform economics
develops internal drug assets
Proprietary Pipeline
ABCL635 data due Q3 2026
this is the rerating bet. phase II data for ABCL635 is due in Q3 2026, and that readout is the first hard test of whether AbCellera can move from partner platform to product owner.
proof point
Key numbers
loss
FY2024 net
Net loss $(162.9)M on $28.8M revenue—operating leverage is negative until milestones and pipeline convert.
$137M
long-term debt
Long-term debt -> money owed beyond one year -> so what: debt is 11% of capital, which is manageable now but less comfortable with negative earnings.
5/100
price stability
Price stability -> how steady the stock trades -> so what: a 5 out of 100 score says this name behaves more like a biotech lottery ticket than a steady compounder.
$(0.55)
FY2024 EPS
Basic and diluted loss per share $(0.55) for FY2024—matches the net loss scale above.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $137M (11% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ABCL right now.
source: institutional data · return history unavailable
What just happened
FY2024 filed
Q4 2024 revenue was $5.1M with a $(0.12) EPS loss—FY revenue fell to $28.8M.
Per AbCellera’s Feb 27, 2025 release: Q4 2024 revenue $5.1M (~18% of FY total); FY2024 revenue $28.8M vs. $38.0M in 2023; net loss $162.9M and $(0.55) per share (basic and diluted).
$5.1M
q4 revenue
$(0.12)
q4 eps
$28.8M
fy2024 revenue
the number that mattered
FY2024 revenue was $28.8M with a deep net loss—quarterly swings from milestones still dominate the story.
source: AbCellera FY2024 press release (Feb 27, 2025)
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is ABCL635 failing to validate the proprietary pipeline.
med
ABCL635 misses in phase II
Phase II data is due in Q3 2026. If that readout disappoints, the market loses its clearest reason to treat AbCellera as more than a partner platform with uneven revenue.
Impact: the proprietary-pipeline rerating case weakens fast, and the stock goes back to being judged on ~$29M Street revenue sketches and a nine‑figure annual loss.
med
partner revenue stays lumpy
FY2024 revenue fell to $28.8M from $38.0M in 2023—milestone and partnership revenue can move sharply quarter to quarter.
Impact: when the top line swings that hard, valuation becomes a confidence exercise more than an earnings exercise.
med
cash burn lasts longer than investors want
FY2024 net loss was $162.9M. The company cited ~$840M in total available liquidity (cash/marketable securities plus non‑dilutive government funding)—that buys time, but not endless time, if internal programs need more capital before partner economics mature.
Impact: the longer losses persist, the more the story shifts from platform upside to runway management.
med
the optionality premium unwinds
A ~$1B market cap on ~$29M of Street revenue sketches (vs. $28.8M FY2024 actual) leaves little valuation support from present operations. If pipeline progress slips, investors can stop paying up for future royalty dreams.
Impact: the stock gets pulled back toward balance-sheet math instead of blue-sky science.
A ~$1B valuation sits on top of a business that did $28.8M in FY2024 revenue while losing $162.9M. That can hold if the pipeline de-risks and partner economics improve. It looks far less forgiving if both stay thin.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical
ABCL635 phase II data
Top-line results are expected in Q3 2026. This is the first major test of whether the proprietary pipeline deserves more of your attention than the platform.
revenue
Whether Street revenue sketches prove too low
FY2024 actual revenue was $28.8M. If milestones do not rebuild, the platform story stays volatile.
cash burn
How fast the runway shortens
~$840M in cited available liquidity is real support. The question is how much of it gets consumed before either royalties or internal assets start carrying more weight.
strategy
Platform first, or pipeline first
Management has made the pivot clear. What matters next is balance: more partner monetization now, or more spend on internal programs that take longer to pay off.
Analyst rankings
coverage depth
thin
in human-speak, this is not a stock with a giant wall of analyst certainty behind it. Trial data and milestone flow matter more than consensus comfort.
earnings visibility
low
A business with sub‑$30M annual revenue and nine‑figure losses is hard to model with much confidence—treat Street estimates as sketches.
valuation anchor
none
No profits means no p/e, and partner revenue is uneven. That leaves the stock trading on pipeline odds, balance-sheet time, and investor patience.
source: institutional data
Institutional activity
institutional ownership data for ABCL is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive